XML 17 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common stock and additional paid-in capital
Retained earnings
Accumulated other comprehensive income (loss)
Beginning balance (in shares) at Dec. 31, 2023   11,098,057    
Balance at beginning of period at Dec. 31, 2023 $ 243,079 $ 70,182 $ 211,925 $ (39,028)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
     Net income 6,021   6,021  
Net unrealized (loss) gain on securities available for sale, net of tax (3,241)     (3,241)
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 2     2
Net unrealized gain (loss) on hedging derivative instruments, net of tax 435     435
Comprehensive income 3,217   6,021 (2,804)
Cash dividends declared (3,896)   (3,896)  
Equity compensation expense 231 $ 231    
Payment to repurchase common stock (in shares)   (8,031)    
Payment to repurchase common stock (211)   (211)  
Issuance of restricted stock (in shares)   32,859    
Proceeds from sale of common stock (in shares)   8,048    
Proceeds from sale of common stock $ 204 $ 204    
Ending balance (in shares) at Mar. 31, 2024 11,130,933 11,130,933    
Balance at end of period at Mar. 31, 2024 $ 242,624 $ 70,617 213,839 (41,832)
Beginning balance (in shares) at Dec. 31, 2024 11,155,528 11,155,528    
Balance at beginning of period at Dec. 31, 2024 $ 252,493 $ 71,944 222,823 (42,274)
Increase (Decrease) in Stockholders' Equity [Roll Forward]        
     Net income 7,077   7,077  
Net unrealized (loss) gain on securities available for sale, net of tax 3,969     3,969
Net unrealized gain on securities transferred from available for sale to held to maturity, net of tax 2     2
Net unrealized gain (loss) on hedging derivative instruments, net of tax (75)     (75)
Comprehensive income 10,973   7,077 3,896
Cash dividends declared (4,031)   (4,031)  
Equity compensation expense 298 $ 298    
Payment to repurchase common stock (in shares)   (10,784)    
Payment to repurchase common stock (277)   (277)  
Issuance of restricted stock (in shares)   43,297    
Proceeds from sale of common stock (in shares)   8,840    
Proceeds from sale of common stock $ 225 $ 225    
Ending balance (in shares) at Mar. 31, 2025 11,196,881 11,196,881    
Balance at end of period at Mar. 31, 2025 $ 259,681 $ 72,467 $ 225,592 $ (38,378)